Annovis Bio reports Q4/FY2024 results; launches Phase 3 AD trial with data expected mid-2026

Annovis Bio, Inc.

Q4 net loss $0.43/share vs $2.24 YoY; FY net loss $2.02 basic, $2.31 diluted vs $6.23 in 2023.
Cash $10.6M at Dec 31, 2024; after $21M stock offering, runway extends to Q4 2025.
Phase 3 early AD trial launched Feb 2025; symptomatic data expected mid-2026, disease-modifying data mid-2027.
FDA cleared Phase 3 early AD trial Oct 2024 based on Phase 2/3 data showing symptomatic improvement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.